Antiproteinuric and blood pressure-lowering effects of fixed combinations of ARB / hydrochlorothiazide in hypertensive patients with chronic kidney disease

Antiproteinuric and blood pressure-lowering effects of fixed combinations of ARB / hydrochlorothiazide in hypertensive patients with chronic kidney disease - Efficacy of fixed combinations of ARB/HCTZ in patients with CKD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001616

Enrollment

Registered

2009-01-03

Start date

2008-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

losartan/HCTZ fixed combination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)CKD stage3,30<eGFR<60mL/min/1.73m-2 2)20<age<80 (years old) 3)hypertensive patients, who were treated with ARB (over 140/90mmHg) 4) Patients with diabetes

Exclusion criteria

Exclusion criteria: 1) Age < 20 or over 80 y/o 2) CKD stage 4-5 3) hypertensive emergency 4) Severe diabetes mellitus 5) Renovascular or endocrine hypertension

Design outcomes

Primary

Measure	Time frame
Blood pressure lowering effect, Change of the urinary protein excretion, Change of the renal function, adverse effects	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026